By Aditya Samal and Leroy Leo (Reuters) -HCA Healthcare Inc said it expects a recovery in surgical procedures to persist through the year for the hospital operator as staffing almost reaches pre-pande[...]
Read more
Health
Altria faces first trial over claims it helped market Juul to teens
By Brendan Pierson (Reuters) – Tobacco giant Altria Group Inc is set to face trial Monday in a lawsuit by San Francisco’s public school district accusing the company of fueling a teen vapi[...]
Read more
US judge halts most talc lawsuits against J&J, stops trials
By Mike Spector NEW YORK (Reuters) -A U.S. judge on Thursday halted most of the tens of thousands of lawsuits alleging Johnson & Johnson’s baby powder and other talc products caused cancer and sto[...]
Read more
US veterans suing 3M over earplugs seek to stop unit’s ‘false alarm’ bankruptcy
By Dietrich Knauth (Reuters) -U.S. veterans and members of the military on Wednesday urged a judge to dismiss 3M’s bid to use the bankruptcy of its subsidiary Aearo Technologies to shield itself[...]
Read more
Abbott signals recovery in device sales as hospital staff shortages ease (April 19)
(This April 19 story has been corrected to say Third Bridge is an “investment research firm”, not “investment consulting firm”, in paragraph 9) By Khushi Mandowara and Leroy Le[...]
Read more
GSK-spinoff Haleon forecasts 2023 organic revenue growth at top-end of view
(Reuters) – Consumer healthcare group Haleon expects 2023 organic revenue growth towards the upper end of its 4%-6% forecast, it said on Thursday, on strong demand and the restocking of its resp[...]
Read more
J&J talc unit asks judge to halt cancer lawsuits as it pursues $8.9 billion settlement
By Dietrich Knauth (Reuters) -A Johnson & Johnson subsidiary is again asking a U.S. judge to pause tens of thousands of lawsuits alleging the company’s baby powder and other talc products ca[...]
Read more
AstraZeneca confident new COVID antibody protects against known variants
By Maggie Fick BARCELONA (Reuters) – AstraZeneca is confident that its new version of COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants, its v[...]
Read more
GSK bets $2 billion on Bellus cough drug to soothe pipeline fears
By Natalie Grover and Aby Jose Koilparambil (Reuters) -GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on res[...]
Read more